Cadila Healthcare receives US FDA's EIR report for Ahmedabad facility
The company has received an Establishment Inspection Report (EIR) from the US drug regulator for its topical manufacturing facility located at Changodar (Ahmedabad)
Cadila Healthcare Ltd’s topical manufacturing facility located at Changodar, Ahmedabad (Gujarat), has received an establishment inspection report (EIR) from the US Food and Drug Administration (FDA) following the inspection carried out in March 2016.
“The receipt of EIR indicates the successful closure of the inspection points (483s) raised. The topical plant is a dedicated facility for manufacturing ointments and does not form a part of the Moraiya formulations manufacturing plant,” said the company in a BSE filing today.
“The receipt of EIR indicates the successful closure of the inspection points (483s) raised. The topical plant is a dedicated facility for manufacturing ointments and does not form a part of the Moraiya formulations manufacturing plant,” said the company in a BSE filing today.